The Technical Analyst
Ironwood Pharmaceuticals [IRWD]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Ironwood Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.10% $8.31
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 300.76 mill |
| EPS: | -6.45 |
| P/E: | -1.290 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 156.53 mill |
| Avg Daily Volume: | 4.63 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.290 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.290 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$19.43 (133.77%) $11.12 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.83 - 8.80 ( +/- 5.84%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Denner Alexander J | Buy | 1 662 | Class A Common Stock |
| 2024-03-08 | John Minardo | Buy | 32 752 | Class A Common Stock |
| 2024-03-08 | John Minardo | Sell | 32 752 | Performance-based Restricted Stock Unit |
| 2024-03-08 | Emany Sravan Kumar | Buy | 37 120 | Class A Common Stock |
| 2024-03-08 | Emany Sravan Kumar | Sell | 37 120 | Performance-based Restricted Stock Unit |
| INSIDER POWER |
|---|
| 45.57 |
| Last 100 transactions |
| Buy: 2 835 189 | Sell: 1 035 601 |
Forecast:
16:00 - $8.31
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.31
Forecast 2: 16:00 - $8.31
Forecast 3: 16:00 - $8.31
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.31 (3.10% ) |
| Volume | 2.11 mill |
| Avg. Vol. | 4.63 mill |
| % of Avg. Vol | 45.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IRWD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.92 | N/A | Active |
|---|
IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-04-08 19:45:00 - Press Release
Ongoing Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ironwood Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 8, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ironwood pharmaceuticals, inc. ("ironwood" or "the company") (nasdaq:irwd) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-05 07:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ironwood Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 5, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ironwood pharmaceuticals, inc. ("ironwood" or "the company") (nasdaq:irwd) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-01 07:00:00 - Press Release
Ongoing Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ironwood Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 1, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ironwood pharmaceuticals, inc. ("ironwood" or "the company") (nasdaq:irwd) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-03-30 18:20:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Ironwood Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / march 30, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ironwood pharmaceuticals, inc. ("ironwood" or "the company") (nasdaq: irwd) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-03-28 07:30:00 - Press Release
Ironwood Pharmaceuticals Announces Positive Results From Its Phase Ii Exploratory Stargaze Trial Of Apraglutide In Patients With Steroid-refractory Gastrointestinal Acute Graft-versus-host Disease (sr Gi Agvhd)
Boston--(business wire)--ironwood pharmaceuticals, inc. (nasdaq: irwd), a gi-focused healthcare company, today announced positive, primary results up to day 91 for its phase ii exploratory stargaze trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute graft-versus-host disease (sr gi agvhd). the primary objective of the trial was to evaluate the safety and tolerability of once-weekly apraglutide, a next-generation, long-acting glucagon-like peptide-2 (glp-2) an.
Latest News
2024-03-05 13:05:07 - InvestorPlace
It's Time! 3 Failing Biotech Stocks to Sell Right Now
Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company.
2024-02-29 08:37:38 - InvestorPlace
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?
Ironwood Pharmaceuticals (NASDAQ: IRWD ) stock is falling on Thursday after the gastrointestinal healthcare company released results from a Phase III clinical trial. This clinical trial covers the use of once-weekly subcutaneous apraglutide as a treatment for short bowel syndrome with intestinal failure (SBS-IF).
2024-02-23 07:30:00 - Business Wire
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference. ASPEN is being held from March 2-5, 2024,.
2024-02-16 10:41:17 - Zacks Investment Research
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
2024-02-15 09:16:04 - Zacks Investment Research
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.20. This compares to earnings of $0.27 per share a year ago.
2024-02-05 09:51:17 - Zacks Investment Research
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-02-01 16:01:00 - Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (647) 495-7514 (international) using conference ID number and event passcode 1057375. To access the webcast, please visit the Investors section of Ironwood's w.
2024-01-23 10:56:06 - Zacks Investment Research
Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-03 16:01:00 - Business Wire
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA. A live audio webcast of Ironwood's presentation will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access.
2023-11-10 12:47:22 - Zacks Investment Research
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.